IP Library Patent Application 16973646
Patent Application
App. No. 16/973,646

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING WOUND, COMPRISING INDIRUBIN DERIVATIVE AS ACTIVE INGREDIENT

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/973,646
Abstract

The present disclosure relates to a composition for preventing or treating wound. The composition according to the present disclosure contains, as an active ingredient, an indirubin derivative alone or one or more selected from a group consisting of an indirubin derivative, an Euodia sutchuenensis Dode extract, methyl vanillate, hesperidin and quercitrin, and thus can be used as a pharmaceutical composition capable of promoting wound healing and reducing scarring not only in a normal state but also in a diabetic state. Furthermore, since the composition exhibits excellent effects in healing diabetic wound as well as general wound, it can be usefully used as a pharmaceutical composition, cosmetic composition or food composition for alleviating, preventing or treating general wound or diabetic wound, or as a veterinary composition for treating diabetic wound.

Claims (26)

1 . A pharmaceutical composition for preventing or treating wound, comprising one or more indirubin derivative selected from Chemical Formulas 1-4 as an active ingredient:

2 . The pharmaceutical composition for preventing or treating wound according to claim 1 , wherein the composition further comprises an Euodia sutchuenensis Dode extract.

3 . The pharmaceutical composition for preventing or treating wound according to claim 1 , wherein the composition further comprises one or more selected from a group consisting of methyl vanillate, hesperidin and quercitrin.

4 . The pharmaceutical composition for preventing or treating wound according to claim 1 , wherein the wound is caused by burn, ulcer, injury, surgical operation, childbirth, chronic wound, diabetic wound or dermatitis.

5 . The pharmaceutical composition for preventing or treating wound according to claim 1 , wherein the pharmaceutical composition is for topical application to skin.

6 . The pharmaceutical composition for preventing or treating wound according to claim 1 , wherein the pharmaceutical composition is prepared into a formulation selected from a group consisting of a cream, a gel, an ointment, an emulsion, a suspension, a spray and a transdermal patch.

7 . The pharmaceutical composition for preventing or treating wound according to claim 1 , wherein the pharmaceutical composition is an emulsion formulation further comprising an oil, a surfactant and a polyethylene glycol.

8 . The pharmaceutical composition for preventing or treating wound according to claim 7 , wherein a mixing weight ratio of the oil, the surfactant and the polyethylene glycol is 0.3-30:1:2-2.5.

9 . The pharmaceutical composition for preventing or treating wound according to claim 1 , wherein the active ingredient is comprised in an amount of 1-20 wt % based on the total weight of the composition.

10 . The pharmaceutical composition for preventing or treating wound according to claim 7 , wherein the surfactant is one or more selected from a group consisting of polyoxyethylene sorbitan monolaurate (Tween 20), polyoxyethylene sorbitan monopalmitate (Tween 40), polyoxyethylene sorbitan monostearate (Tween 60) and polyoxyethylene sorbitan oleate (Tween 80).

11 . The pharmaceutical composition for preventing or treating wound according to claim 7 , wherein the oil is one or more selected from a group consisting of polyethoxylated castor oil (Kolliphor® EL), sunflower oil and olive oil.

12 . The pharmaceutical composition for preventing or treating wound according to claim 7 , wherein the composition further comprises a cyclodextrin and the cyclodextrin is comprised in an amount of 100-1000 parts by weight based on 100 parts by weight of the active ingredient present in the composition.

13 . The pharmaceutical composition for preventing or treating wound according to claim 7 , wherein the emulsion formulation is a stable formulation not exhibiting change in Wnt activity and solubility in distilled water at 4-25° C. for 3 months.

14 . A pharmaceutical composition for a non-human animal for treating or alleviating wound, comprising one or more indirubin derivative selected from Chemical Formulas 1-4 as an active ingredient:

15 . A cosmetic composition for preventing or alleviating wound, comprising one or more indirubin derivative selected from Chemical Formulas 1-4 as an active ingredient:

16 . The cosmetic composition for preventing or alleviating wound according to claim 15 , wherein the composition further comprises an Euodia sutchuenensis Dode extract.

17 . The cosmetic composition for preventing or alleviating wound according to claim 15 , wherein the composition further comprises one or more selected from a group consisting of methyl vanillate, hesperidin and quercitrin.

18 . The cosmetic composition for preventing or alleviating wound according to claim 15 , wherein the cosmetic composition is an emulsion formulation further comprising an oil, a surfactant and a polyethylene glycol.

19 . The cosmetic composition for preventing or alleviating wound according to claim 15 , wherein a mixing weight ratio of the oil, the surfactant and the polyethylene glycol is 0.3-30:1:2-2.5.

20 . The cosmetic composition for preventing or alleviating wound according to claim 15 , wherein the active ingredient is comprised in an amount of 1-20 wt % based on the total weight of the composition.

21 . The cosmetic composition for preventing or alleviating wound according to claim 18 , wherein the surfactant is one or more selected from a group consisting of polyoxyethylene sorbitan monolaurate (Tween 20), polyoxyethylene sorbitan monopalmitate (Tween 40), polyoxyethylene sorbitan monostearate (Tween 60) and polyoxyethylene sorbitan oleate (Tween 80).

22 . The cosmetic composition for preventing or alleviating wound according to claim 18 , wherein the oil is one or more selected from a group consisting of polyethoxylated castor oil (Kolliphor® EL), sunflower oil and olive oil.

23 . The cosmetic composition for preventing or alleviating wound according to claim 18 , wherein the composition further comprises a cyclodextrin and the cyclodextrin is comprised in an amount of 100-1000 parts by weight based on 100 parts by weight of the active ingredient present in the composition.

24 . A food composition for preventing or alleviating wound, comprising one or more indirubin derivative selected from Chemical Formulas 1-4 as an active ingredient:

25 . The food composition for preventing or alleviating wound according to claim 24 , wherein the composition further comprises an Euodia sutchuenensis Dode extract.

26 . The food composition for preventing or alleviating wound according to claim 24 , wherein the composition further comprises one or more selected from a group consisting of methyl vanillate, hesperidin and quercitrin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2020
From: CHOI, KANG-YELL; KIM, EUNHWAN; SEO, SEOL HWA; YOON, MINGUEN
To: CK BIOTECH
Reel/Frame 054595/0707 →